Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Cancers|October 17, 2019
RAD52 as a Potential Target for Synthetic Lethality-Based Anticancer TherapiesMonika Toma, Katherine Sullivan-Reed, Tomasz Śliwiński, et al.
Medicinal Chemistry Research : an International Journal for Rapid Communications on Design and Mechanisms of Action of Biologically Active Agents|October 19, 2020
Novel allosteric PARP1 inhibitors for the treatment of BRCA-deficient leukemiaElizabeth Hewlett, Monika Toma, Katherine Sullivan-Reed, et al.
Molecular Cancer Research : MCR|June 26, 2023
Simultaneous Targeting of DNA Polymerase Theta and PARP1 or RAD52 Triggers Dual Synthetic Lethality in Homologous Recombination-Deficient Leukemia CellsKatherine Sullivan-Reed, Monika M Toma, Malgorzata Drzewiecka, et al.
Cell Reports|March 10, 2021
Polθ promotes the repair of 5'-DNA-protein crosslinks by microhomology-mediated end-joiningGurushankar Chandramouly, Shuren Liao, Timur Rusanov, et al.
Nature Communications|July 10, 2024
PARG is essential for Polθ-mediated DNA end-joining by removing repressive poly-ADP-ribose marksUmeshkumar Vekariya, Leonid Minakhin, Gurushankar Chandramouly, et al.
Molecular Cancer Research : MCR|June 22, 2017
IGH/MYC Translocation Associates with BRCA2 Deficiency and Synthetic Lethality to PARP1 InhibitorsSilvia Maifrede, Kayla Martin, Paulina Podszywalow-Bartnicka, et al.
Cancer Letters|February 1, 2025
ZNF251 haploinsufficiency confers PARP inhibitors resistance in BRCA1-mutated cancer cells through activation of homologous recombinationHuan Li, Srinivas Chatla, Xiaolei Liu, et al.
Nature Communications|September 29, 2019
Molecular basis of microhomology-mediated end-joining by purified full-length PolθSamuel J Black, Ahmet Y Ozdemir, Ekaterina Kashkina, et al.
Nature Communications|April 11, 2020
Publisher Correction: Molecular basis of microhomology-mediated end-joining by purified full-length PolθSamuel J Black, Ahmet Y Ozdemir, Ekaterina Kashkina, et al.
Cell Reports|June 14, 2018
Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor CellsKatherine Sullivan-Reed, Elisabeth Bolton-Gillespie, Yashodhara Dasgupta, et al.
Pageof 2